Substance / Medication

Citalopram hydrobromide

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

247 trials linked to this intervention

247
Total Trials
40
Recruiting
106
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Comparative Analysis of Secondary Outcomes in Treatment of Charcot Neuropathy: A Systematic Review.
Nsekpong Tyler B, Amin Atish S, Ali Shahrukh R et al. · Foot Ankle Spec · 2025
PMID: 35778875Meta-Analysis
Genetic Signature for the Causation of Charcot Neuro-osteoarthropathy of Foot in Diabetes: A Systematic Review.
Sharma Sonali, Rastogi Ashu · Int J Low Extrem Wounds · 2025
PMID: 38711285Meta-Analysis
Content and effects of balance training in people with diabetic peripheral neuropathy - a systematic review and meta-analysis.
Køhler Esben, Dalgas Ulrik, Buhl Christian Selmer et al. · Physiother Theory Pract · 2025
PMID: 39162012Meta-Analysis
The Landscape of Products for Diabetic Peripheral Neuropathy: A Scientific and Patent Systematic Review.
Dos Santos Barros Giselda, Dos Passos Menezes Paula, de Cassia Silva Simone et al. · Recent Pat Biotechnol · 2025
PMID: 39253935Meta-Analysis
Decompressive Nerve Surgery Associated with Low Diabetic Foot Ulcer Rate and High-Risk Bias: A Systematic Review and Meta-Analysis.
Louca Milton, Meares Charles, Dusseldorp Joseph R · Plast Reconstr Surg · 2025
PMID: 39265064Meta-AnalysisFull text (PMC)
Effect of the glucagon-like peptide-1 receptor agonists on diabetic peripheral neuropathy: A meta-analysis.
Fan Shujin, Qiu Yue, Liu Jing et al. · J Neurochem · 2025
PMID: 39453834Meta-Analysis
Weaning From Tobacco with Nicotine or Varenicline in Severe and Mild Tobacco Dependence—Findings of a Meta-Analysis.
Selbach Claudia, Siebel Christian, Lilienthal Jona et al. · Dtsch Arztebl Int · 2025
PMID: 39628402Meta-AnalysisFull text (PMC)
Effect of pain neuroscience education(PNE) in people with different mechanisms of chronic pain: A systematic review and meta-analysis.
Tatikola Sripada Pallavi, Natarajan Venkatesh, Amaravadi Sampath Kumar et al. · J Bodyw Mov Ther · 2025
PMID: 39663091Meta-Analysis
The safety and efficacy of stem cell therapy for diabetic peripheral neuropathy in animal studies: A systematic review and meta-analysis.
Alizadeh Seyed Danial, Hassan Zadeh Tabatabaei Mahgol Sadat, Rezaei Zadeh Rukerd Mohammad et al. · Neuroscience · 2025
PMID: 39706518Meta-Analysis
Multi-ancestry meta-analysis of tobacco use disorder identifies 461 potential risk genes and reveals associations with multiple health outcomes.
Toikumo Sylvanus, Jennings Mariela V, Pham Benjamin K et al. · Nat Hum Behav · 2024
PMID: 38632388Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Citalopram hydrobromide (substance)
SNOMED CT
116521005
UMLS CUI
C0724555

Clinical Data

This intervention maps to 14 entities in the Ltrl knowledge graph.

8
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
247
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.